leadf
logo-loader
viewKintara Therapeutics

Dawson James issues Buy rating on Kintara Therapeutics as its VAL-083 selected for study to treat three major brain cancers

In the 800-patient study by the Global Coalition for Adaptive Research, Kintara's drug is the only one being studied for the 3 forms of brain cancer while two other rival drugs will only target singular cancers

Kintara Therapeutics - Dawson James Securities on Thursday issued a Buy rating on Kintara Therapeutics Inc (NASDAQ:KTRA), noting that the company’s drug VAL-083 has a notable status in a major brain-cancer study
Meanwhile, the analyst firm has a $4 price target on the stock -- which recently traded around $1.80 a share in New York  

Dawson James Securities on Thursday issued a Buy rating on Kintara Therapeutics Inc (NASDAQ:KTRA), noting that the company’s drug VAL-083 has a notable status in a major brain-cancer study. 

In the 800-patient study by the Global Coalition for Adaptive Research, the analyst firm noted that “Kintara’s VAL-083 is the only compound in the study that is going to be evaluated in all three major cancer types" -- newly diagnosed unmethylated (NDUM), recurrent glioblastoma (GBM), and newly diagnosed methylated MGMT. 

Two other drug-makers will participate in the study, also called the GCAR Adaptive Study, which will split patients into three arms. Again, “each company will evaluate their respective therapeutic, but only VAL-083 will be evaluated in three active arms,” analyst Jason Kolbert wrote.

READ: Kintara Therapeutics says enrollment has begun for innovative Phase 2/3 trial of VAL-083 for glioblastoma

The study is now underway with 34 active sites and 357 screened patients, the analyst noted.

Meanwhile, Kolbert has a $4 price target on the stock -- which recently traded around $1.80 a share in New York.  

VAL-083 is considered a first-in-class, DNA-targeting small molecule, mechanisms of action (MOA) in addendum, which is designed to cross the blood-brain barrier. It has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors in clinical trials sponsored by the US National Cancer Institute.

VAL-083 has been granted Orphan Drug Designation for GBM by the US Food & Drug Administration (FDA) and the European Medicines Agency (EMA) and has also been granted Orphan Drug Designations for medulloblastoma and ovarian cancer from the FDA. As well, the FDA has granted Fast Track Designation for VAL-083 in recurrent GBM.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Kintara Therapeutics

Price: 1.71 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $52.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

FansUnite Entertainment files paperwork for B2B and B2C gambling license in U.K.

FansUnite Entertainment (CSE: FANS- OTCQB: FUNFF) President Darius Eghdami joined Steve Darling from Proactive with news its subsidiaries, Askott Entertainment has filed applications for both Business-to-Business and Business-to-Consumer gambling licenses with the U.K. Gambling...

14 hours, 5 minutes ago

2 min read